Cohance Lifesciences (BOM:543064) Long-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543064 Cohance Lifesciences Ltd BOM:543064
87 GF Score
Price ₹449.05
GF Value ₹644.88
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Cohance Lifesciences Long-Term Debt?

Cohance Lifesciences BOM:543064 -2.93% 87 Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹644.88 (Possible Value Trap). The stock has 8 warning signs investors should review.

Cohance Lifesciences's Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Cohance Lifesciences's quarterly Long-Term Debt increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹505 Mil) but then declined from Mar. 2026 (₹505 Mil) to Jun. 2026 (₹0 Mil).

Cohance Lifesciences's annual Long-Term Debt increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹62 Mil) and increased from Mar. 2025 (₹62 Mil) to Mar. 2026 (₹505 Mil).

Cohance Lifesciences  (BOM:543064) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Cohance Lifesciences Long-Term Debt Related Terms

Cohance Lifesciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Cohance Lifesciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cohance Lifesciences Long-Term Debt Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial 284.40 45.64 0.00 62.40 504.80

Cohance Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 728.60 0.00 504.80 0.00
BOM:543064
87GF Score
Cohance Lifesciences Ltd BOM:543064
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Cohance Lifesciences (BOM:543064) has a Long-Term Debt of ₹0 Mil as of Jun. 2026.
Is Cohance Lifesciences' Long-Term Debt too high?
Cohance Lifesciences' current Long-Term Debt is ₹0 Mil. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Long-Term Debt compare to ZTS?
Cohance Lifesciences' Long-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Cohance Lifesciences's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹644.88, compared to a current price of ₹449.05 — trading 30.4% below its estimated fair value. The current Long-Term Debt is ₹0 Mil. Cohance Lifesciences' overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?

Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued. The current stock price of ₹449.05 is trading 30.4% below its estimated GF Value™ of ₹644.88. GuruFocus considers Cohance Lifesciences to be Possible Value Trap.

Key valuation signals for BOM:543064:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹644.88 vs. price of ₹449.05 (30.4% below fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cohance Lifesciences Business Description

Other Exchanges COHANCE:India
Address Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score

Get the complete analysis for BOM:543064

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹449.05
Price
₹644.88
GF Value